Company intelligence / Profile preview

Suzhou Centergene Pharmaceuticals Co., Ltd.

Ownership: Public · CNTGF
Development stage: Phase 3

Overview

Centergene focuses on developing recombinant protein drugs. Its lead program, SJ02 (FSH-CTP), has filed for Biologics License Application (BLA). Other programs include additional reproductive hormones and corticotropin in pre-commercial or late-stage development.[5][3]

Therapeutic areas: Endocrinology
Modalities: Recombinant proteins
Industry: Biotech

Drug pipeline

1 asset

SJ02

Phase 3

Indications: Infertility, Assisted reproductive technology

Beyond the preview

Go deeper on Suzhou Centergene Pharmaceuticals Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Centergene Pharmaceuticals Co., Ltd..

Explore the full profile